Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations

Journal of Clinical Endocrinology and Metabolism

Volumn 92, Issue 5, 2007, Pages 1881-1885

  Altinova, Alev E ^a,b   Arslan, Metin ^a   Sepici Dincel, Aylin ^a   Akturk, Mujde ^a   Altan, Nilgun ^a   Toruner, Fusun B ^a  

^a GAZI UNIVERSITY   (Turkey)

^b NONE   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; N(G),N(G) DIMETHYLARGININE; BIOLOGICAL MARKER; DIMETHYLARGININE; DRUG DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PRIORITY JOURNAL; REGRESSION ANALYSIS; ADOLESCENT; BLOOD; DEFENSE MECHANISM; METABOLISM; MIDDLE AGED;

ADOLESCENT; ADULT; ARGININE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 1; FEMALE; HUMANS; MALE; MIDDLE AGED; REGRESSION (PSYCHOLOGY);

EID: 34249851106     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2006-2643     Document Type: Article

References (33)

1. Palmer RM, Ferrige AG, Moncada S 1987 Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327:524-526
2. Vallance P, Chan N 2001 Endothelial function and nitric oxide: clinical relevance. Heart 85:342-350
3. Boger RH 2003 The emerging role of ADMA as a novel cardiovascular risk factor. Cardiovasc Res 59:824-833
4. Boger RH 2004 Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor. J Nutr 134:2842S-2847S
5. Vallance P, Leone A, Calver A, Collier J, Moncada S 1992 Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 339:572-575
6. Boger RH, Bode-Boger SM, Szuba A, Tsao PS, Chan JR, Tangphao O, Blaschke TF, Cooke JP 1998 Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98:1842-1847
7. Perticone F, Sciacqua A, Maio R, Perticone M, Maas R, Boger RH, Tripepi G, Sesti G, Zoccali C 2005 Asymmetric dimethylarginine, l-arginine, and endothelial dysfunction in essential hypertension. J Am Coll Cardiol 46:518-523
8. Chan NN, Chan JC 2002 Asymmetric dimethylarginine (ADMA): a potential link between endothelial dysfunction and cardiovascular diseases in insulin resistance syndrome? Diabetologia 45:1609-1616
9. Ito A, Tsao PS, Adimoolam S, Kimoto M, Ogawa T, Cooke JP 1999 Novel mechanism for endothelial dysfunction: dysregulation of dimethylarginine dimethylaminohydrolase. Circulation 99:3092-3095
10. Miyazaki H, Matsuoka H, Cooke JP, Usui M, Ueda S, Okuda S, Imaizumi T 1999 Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 99:1141-1146
11. Zoccali C, Bode-Boger SM, Mallamaci F, Benedetto FA, Tripepi G, Malatino L, Cataliotti A, Bellanuova I, Fermo I, Frolich JC, Boger R 2001 Asymmetric dimethylarginine (ADMA): an endogenous inhibitor of nitric oxide synthase predicts mortality in end-stage renal disease (ESRD). Lancet 358:2113-2117
12. Bode-Boger SM, Boger RH, Kienke S, Junker W, Frolich JC 1996 Elevated L-arginine/dimethylarginine ratio contributes to enhanced systemic NO production by dietary L-arginine in hypercholesterolemic rabbits. Biochem Biophys Res Commun 219:598-603
13. Schalkwijk CG, Stehouwer CD 2005 Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci (Lond) 109:143-159
14. Chan NN, Vallance P, Colhoun HM 2000 Nitric oxide and vascular responses in type I diabetes. Diabetologia 43:137-147
15. Chan NN, Vallance P, Colhoun HM 2003 Endothelium-dependent and -independent vascular dysfunction in type 1 diabetes: role of conventional risk factors, sex, and glycemic control. Arterioscler Thromb Vasc Biol 23:1048-1054
16. Correa RC, Alfieri AB 2003 Plasmatic nitric oxide, but not von Willebrand Factor, is an early marker of endothelial damage, in type 1 diabetes mellitus patients without microvascular complications. J Diabetes Complications 17:264-268
17. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus 2006 Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 29(Suppl 1):43-48
18. Chen BM, Xia LW, Zhao RQ 1997 Determination of NC, NG-dimethylarginine in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 692:467-471
19. Tarnow L, Hovind P, Teerlink T, Stehouwer CD, Parving HH 2004 Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 27:765-769
20. Mittermayer F, Pleiner J, Krzyzanowska K, Wiesinger GF, Francesconi M, Wolzt M 2005 Regular physical exercise normalizes elevated asymmetrical dimethylarginine concentrations in patients with type 1 diabetes mellitus. Wien Klin Wochenschr 117:816-820
21. Yasuda S, Miyazaki S, Kanda M, Goto Y, Suzuki M, Harano Y, Nonogi H 2006 Intensive treatment of risk factors in patients with type-2 diabetes mellitus is associated with improvement of endothelial function coupled with a reduction in the levels of plasma asymmetric dimethylarginine and endogenous inhibitor of nitric oxide synthase. Eur Heart J 27:1159-1165
22. Krzyzanowska K, Mittermayer F, Krugluger W, Schnack C, Hofer M, Wolzt M, Schernthaner G 2006 Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes. Atherosclerosis 189:236-240
23. Paiva H, Lehtimaki T, Laakso J, Ruokonen I, Rantalaiho V, Wirta O, Pasternack A, Laaksonen R 2003 Plasma concentrations of asymmetric- dimethylarginine in type 2 diabetes associate with glycemic control and glomerular filtration rate but not with risk factors of vasculopathy. Metabolism 52:303-307
24. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, Tsuji H, Reaven GM, Cooke JP 2002 Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 106:987-992
25. Sorrenti V, Mazza F, Campisi A, Vanella L, Li Volti G, Di Giacomo C 2006 High glucose-mediated imbalance of nitric oxide synthase and dimethylarginine dimethylaminohydrolase expression in endothelial cells. Curr Neurovasc Res 3:49-54
26. Kimoto M, Whitley GS, Tsuji H, Ogawa T 1995 Detection of NG, NG-dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. J Biochem 117:237-238
27. Leiper JM, Santa Maria J, Chubb A, MacAllister RJ, Charles IG, Whitley GS, Vallance P 1999 Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J 343:209-214
28. Maas R 2005 Pharmacotherapies and their influence on asymmetric dimethylargine (ADMA). Vasc Med 10(Suppl 1):S49-S57
29. Eid HM, Arnesen H, Hjerkinn EM, Lyberg T, Seljeflot I 2004 Relationship between obesity, smoking, and the endogenous nitric oxide synthase inhibitor, asymmetric dimethylarginine. Metabolism 53:1574-1579
30. Boger RH, Sydow K, Borlak J, Thum T, Lenzen H, Schubert B, Tsikas D, Bode-Boger SM 2000 LDL cholesterol up-regulates synthesis of asymmetrical dimethylarginine in human endothelial cells: involvement of S- adenosylmethionine-dependent methyltransferases. Circ Res 87:99-105
31. Jia SJ, Jiang DJ, Hu CP, Zhang XH, Deng HW, Li YJ 2006 Lysophosphatidylcholine-induced elevation of asymmetric dimethylarginine level by the NADPH oxidase pathway in endothelial cells. Vasc Pharmacol 44:143-148
32. Bae SW, Stuhlinger MC, Yoo HS, Yu KH, Park HK, Choi BY, Lee YS, Pachinger O, Choi YH, Lee SH, Park JE 2005 Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment. Am J Cardiol 95:729-733
33. Eid HM, Eritsland J, Larsen J, Arnesen H, Seljeflot I 2003 Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis 166:279-284